Clinical Trial Update: Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating fostamatinib for chronic active antibody-mediated rejection in renal transplant patients is currently active and not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplant Rejection

Drugs mentioned

• Fostamatinib (fostamatinib)

Snippet

Sponsor: Imperial College London | Conditions: Renal Transplant Rejection | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING